Gumintad, Lea Mae P.

HRN: 24-99-46  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/10/2024
CEFUROXIME 750MG (VIAL)
07/10/2024
07/17/2024
IV
120mg
Q8
Toxic Megacolon Sec To Hirschsprung’s Disease S/P Diverting Colostomy (05-18-23)
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Intra-abdominalProphylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: